Bacterial and microbial infections both systemic, as well as topical, are a major health issue worldwide. Furthermore, antibiotic overuse, as well as not completing prescribed courses of antibiotics, has created a generation of resistant bacteria that, once they have invaded our bodies makes treatment very difficult. Studies at various institutions around the globe found that CHD-FA™ was successful in not only killing a wide variety of organism but also has the following effects:
Works synergistically with other medicines.
Is effective against a wide variety of resistant bacteria.
Anti-bacterial studies on CHD-FA™, including peer-reviewed and published articles.
CHD-FA™ is a highly promising topical agent to enhance healing of wounds infected with drug-resistant pathogens. This peer-reviewed and published work was done at Public Health Research Institute Rutgers-New Jersey Medical School. The study proved that CHD-FA™ is effective against the ‘super-bug’, methicillin-resistant Staphylococcus aureus, a powerful microbe that has become a major concern worldwide.
Biological properties of CHD-FA™ as a potential novel therapy for the management of oral biofilm infections. This work is done at the world-famous Glasgow Dental School, School of Medicines that was peer-reviewed and published. This study concluded that CHD-FA™ exhibits broad-spectrum antimicrobial activity against orally-relevant biofilm organisms.
Synergistic effect of CHD-FA™. The results of this study conducted at the University of Pretoria showed that CHD-FA™ has antimicrobial activity against Staphylococcus aureus, multidrug-resistant Staphylococcus aureus (MRSA), Escherichia coli, Pseudomonas aeruginosa and Candida albicans. The antimicrobial spectrum of CHD-FA™ compares favourably with that of currently prescribed antibiotics and acts synergistically with oxacillin (methicillin) and gentamicin. A Gram stain of C. albicans grown in the presence of CHD-FA™ showed rounded enlarged non-dividing bodies indicating that this product acts on the cell wall of microorganisms.
Assessment of the in vitro efficacy of CHD-FA ± Oxacillin following several passages in methicillin-resistant Staphylococcus aureus (EMRSA16). This study at EuproTec in the UK indicated that there is no resistance build-up by CHD-FA™.
Determination of the in vitro efficacy of CHD-FA™ against Multi-Resistant Enterobacteriaceae and Mycobacteria. The study concluded:
CHD-FA™ was effective against NDM-1, KPC and ESBL positive Klebsiella pneumonia and multi-resistant E. coli strains with a 100% MIC value of 0.06-0.12%.
CHD-FA™ was highly effective against multi-resistant Gram-negative bacilli including NDM-1 positive strains. CHD-FA was also highly effective against Mycobacterium smegmatis. All organisms were inhibited using ≤0.12% of CHD-FA™.